Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain.
The treatment landscape of metastatic urothelial carcinoma (mUC) has evolved with the emergence of programmed cell death protein 1/ligand 1 (PD-1/L1) inhibitors. This study assessed mUC treatment patterns in Europe. Data were derived from the …